Dermatovenereology of Russian Federation in 2020: Working Under a Pandemic

Kubanov, Alexey А.; Алексеевич, Кубанов Алексей; Богданова, Е. В.; Витальевна, Богданова Елена

doi:10.25208/vdv1261

Cited by 15 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По данным официального государственного статистического наблюдения, распространенность и заболеваемость АтД всего населения Российской Федерации (РФ) в 2022 г. составила 384,7 и 157,1 случаев на 100 тыс. населения соответственно [3,4]. В немецкоязычных странах среди пациентов с АтД, обращающихся к врачудерматовенерологу, у 25% выявляется АтД средней или тяжелой степени тяжести [5].…”

Section: Bulletin Of Rsmu 1 2024 Vestnikrgmuru | |unclassified

Mutacii 2282del4, R501X, R2447X, S3247X fillagrina pri atopicheskom dermatite

Вербенко,

Карамова,

Чикин

et al. 2024

Вестник РГМУ

View full text Add to dashboard Cite

Atopicheskij dermatit (AtD) — shiroko rasprostranennoe mul'tifaktornoe geneticheski determinirovannoe vospalitel'noe zabolevanie kozhi, obuslovlennoe sredi prochih prichin narusheniem funkcij epidermal'nogo bar'era. Nulevye mutacii gena filaggrina — vazhnogo komponenta sistemy natural'nogo uvlazhnyayushchego faktora, privodyashchie k otsutstviyu vyrabotki polnocennogo belka-predshestvennika, associirovany s AtD. Cel' issledovaniya — ocenit' chastotu naibolee rasprostranennyh v evropejskih populyaciyah nulevyh mutacij gena filaggrina 2282delACTG (rs558269137), R501X (rs61816761), S3247X (rs150597413), R2447X (rs138726443) u vzroslyh pacientov so srednetyazheloj i tyazheloj stepen'yu AtD. Analiz proveden u 99 vzroslyh pacientov oboih polov v vozraste 18–68 let, so srednetyazhelym i tyazhelym AtD. Identifikaciyu mutacij osushchestvlyali s pomoshch'yu razrabotannogo metoda mul'tipleksnogo analiza chetyrekh odnonukleotidnyh polimorfizmov pri ispol'zovanii minisekvenirovaniya. CHastota vstrechaemosti nulevoj mutacii filaggrina 2282delACTG okazalas' na urovne 5,3%, R501X — na urovne 0,5%, R2447X — na urovne 1%. Nulevaya mutaciya S3247X gena FLG v vyborke pacientov ne obnaruzhena. Sravnenie rezul'tatov s rossijskimi i evropejskimi vyborkami vyyavilo sopostavimyj uroven' analiziruemyh mutacij gena filaggrina u vzroslyh pacientov s AtD iz razlichnyh regionov Rossijskoj Federacii.

show abstract

Section: Bulletin Of Rsmu 1 2024 Vestnikrgmuru | |unclassified

Mutacii 2282del4, R501X, R2447X, S3247X fillagrina pri atopicheskom dermatite

Вербенко,

Карамова,

Чикин

et al. 2024

Вестник РГМУ

View full text Add to dashboard Cite

show abstract

Congenital Syphilis: a Review of Global Epidemiology

Gilmour

Walls

2023

Clin Microbiol Rev

View full text Add to dashboard Cite

show abstract

Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery

Namazova-Baranova,

Ambarchyan,

Ivanchikov

et al. 2023

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Background. Psoriasis is an independent risk factor for cardiovascular diseases (CVD). One of the markers associated with the CVD course is epicardial fatty tissue (EFT) that is thicker in psoriasis patients. EFT assessment can be used as a useful indicator of CVD in psoriasis patients. The data about the effect of genetically engineered biological therapy (GEBT), used for psoriasis management, on the EFT thickness is limited. Examination of GEBT effects on EFT may improve our understanding of CVD prevention in psoriasis patients.Objective. The aim of the study is to study the changes in EFT thickness on GEBT.Methods. A prospective cohort study included 56 children with severe and moderate psoriasis. Patients underwent transthoracic two-dimensional echocardiography (M-mode) with EFT thickness assessment and PASI (Psoriasis Area and Severity Index) scoring before the GEBT initiation. All the parameters were re-evaluated after 16 weeks. All patients were divided into three groups according to the initiated therapy: adalimumab, secukinumab and ustekinumab. When dividing the therapy received into groups, the age of the patients was taken into account: inclusion in the adalimumab group was carried out from 4 years, in the secukinumab and ustekinumab groups — from 6 years. Otherwise, the process of group assignment was random. The study results were processed using descriptive statistics methods: the changes in EFT thickness in individual groups were compared via the Wilcoxon test, and results were considered statistically significant at p 0.05.Results. Before the start of therapy, in 56 patients the mean of EFT thickness was 2.11 mm, the mean PASI — 18.32. The adalimumab group had the following indicators: the mean EFT thickness before the therapy was 2.1 mm, and it has decreased to 1.77 mm after 16 weeks of therapy. The mean change in EFT thickness was 0.33 mm, and the median — 0.17 mm [CI 0.33 ± 0.25]. The ustekinumab group: the mean EFT thickness before the therapy was 2.13 mm, 16 weeks after — 1.69 mm. The mean change in EFT thickness was 0.44 mm, and the median — 0.38 [CI 0.44 ± 0.13]. The secukinumab group: the mean EFT thickness before the therapy was 2.08 mm, 16 weeks after — 1.82 mm. The mean change in EFT thickness was 0.27 mm, and the median — 0.27 [CI 0.27 ± 0.07]. Evaluation of indicators via Wilcoxon test has shown statistically significant decrease in the EFT after therapy in all groups (p 0.05). 73% of patients achieved PASI 50, and 6% — PASI 75 in the adalimumab group. 21% of patients did not achieve PASI 50. The mean PASI score before therapy was 16.73 points, and after 16 ± 4 weeks — 6.4 points, the mean dynamics was 10.33 points, the median dynamics was 7 points [CI 10.33 ± 4]. All patients achieved PASI 50, 75.3% — PASI 75, 8% — PASI 90, and 16.7% — PASI 100 in the ustekinumab group. The mean PASI score before therapy was 22.17 points, and after 16 weeks — 3.67 points, the mean dynamics was 19.28 points, the median dynamics was 17 points [CI 18.5 ± 3.03]. All patients achieved PASI 50, 47% — PASI 75, and 11% — PASI 90 in the secukinumab group. The median PASI before therapy was 14.29 points, and after 16 ± 4 weeks — 3.71 points, the mean PASI score before therapy was 14.29 points, and after 16 weeks — 3.7 points, the mean dynamics was 10.59 points, the median dynamics was 10 points [CI 10.59 ± 2.27]. Evaluation of indicators via Wilcoxon test has shown statistically significant decrease in the PASI after therapy in all groups (p 0.05). There were no adverse events leading to cessation of therapy during the follow-up period.Conclusion. All groups have shown decrease in the in EFT thickness and in the PASI score. The most significant dynamics was observed in the ustekinumab group. Research limitations were the small patients sample and the absence of a control group (participants without psoriasis).

show abstract

Dermatovenereology of Russian Federation in 2020: Working Under a Pandemic

Cited by 15 publications

References 1 publication

Mutacii 2282del4, R501X, R2447X, S3247X fillagrina pri atopicheskom dermatite

Mutacii 2282del4, R501X, R2447X, S3247X fillagrina pri atopicheskom dermatite

Congenital Syphilis: a Review of Global Epidemiology

Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery

Contact Info

Product

Resources

About